Effects of Cyclo-His-Pro-enriched yeast hydrolysate on blood glucose levels and lipid metabolism in obese diabetic ob/ob mice.
10.4162/nrp.2016.10.2.154
- Author:
Eun Young JUNG
1
;
Yang Hee HONG
;
Chung PARK
;
Hyung Joo SUH
Author Information
1. Department of Home Economic Education, Jeonju University, Jeonju 55069, Korea.
- Publication Type:Original Article
- Keywords:
Yeast hydrolysate;
blood glucose;
diabetes mellitus;
cyclo-his-pro
- MeSH:
Adipose Tissue;
Animals;
Blood Glucose*;
Body Weight;
Cholesterol;
Diabetes Mellitus;
Dietary Supplements;
Glucose;
Hyperlipidemias;
Insulin;
Lipid Metabolism*;
Lipoproteins;
Mice*;
Yeasts*
- From:Nutrition Research and Practice
2016;10(2):154-160
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/OBJECTIVES: We examined the hypoglycemic and anti-hyperlipidemic effect of yeast hydrolysate (YH) enriched with Cyclo-His-Pro (CHP) in the C57BL/6J ob/ob mouse model. MATERIALS/METHODS: Mice were separated into 4 groups (8 mice/group) on the basis of blood glucose and body weight: WT control, lean mice given vehicle; ob/ob control, ob/ob mice given vehicle; YH-1, ob/ob mice given 0.5 g/kg of YH; YH-2, ob/ob mice given 1 g/kg of YH. YH in saline or vehicle was administered orally in the same volume every day for 3 weeks. RESULTS: Mice treated with YH (0.5 and 1 g/kg) for 3 weeks displayed a significant reduction in overall body weight gain and perirenal and epididymal adipose tissue weight compared to the ob/ob control group. Additionally, high-density lipoprotein (HDL) cholesterol, glucose, and atherogenic indexes were significantly decreased in the blood of YH-1 and YH-2 groups compared to the ob/ob control. In ob/ob mice, YH administration significantly improved glucose tolerance and blood insulin levels. These data indicate that YH treatment produces potent hypoglycemic and anti-hyperlipidemic effects by controlling body weight, fat mass, blood lipid, insulin levels, and glucose tolerance. CONCLUSION: YH could potentially be used as a treatment option for diabetes and hyperlipidemia. The CHP-enriched YH may be a promising strategy in the development of hypoglycemic peptide nutraceuticals.
